Cervical and upper thoracic esophageal cancer (ESCA) presents treatment challenges due to limited clinical evidence. This multi-center study (ChC\&UES) explores radical radio(chemo)therapy efficacy and safety
Age 18 and older.
Confirmation of esophageal cancer through histopathology or cytology.
Primary tumor location within the cervical or upper thoracic segment, extending from the upper esophageal sphincter to the azygos vein.
Absence of distant metastasis.
Receipt of radiation dose below 50Gy.
History of other malignancies (except for cured cancer in situ and malignancies cured for over 5 years) or laryngeal invasion.
Diagnosis of double primary esophageal cancer.
Prior chest radiation therapy within the past 5 years.
Hebei Medical University Fourth Hospital
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Collaborator
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborator
Fujian Cancer Hospital
Collaborator
Fudan University
Collaborator
Shandong Cancer Hospital and Institute
Collaborator